Previous 10 | Next 10 |
Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma. The global m...
ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved Autologous CAR T Therapy ALLO-715 Was Well Tolerated with No Graft-vs-Host Disease and Man...
ALPHA Trials Demonstrate Potential for AlloCAR T™ Therapy to be a Safe and Durable Alternative to Autologous Cell Therapy in CAR T Naïve Patients AlloCAR T Therapy was Associated with Consistent and Manageable Safety with No DLTs or GvHD; Low Rates of Grade 3 ICANs and C...
After a sharp decline last month, gene editing stocks led by Intellia Therapeutics (NTLA +18.9%) have recorded double-digit gains today. Notable gainers include Beam Therapeutics (BEAM +16.4%), Editas Medicine (EDIT +13.6%) and CRISPR Therapeutics (CRSP +11.1%). As shown in the graph, the gro...
Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic C...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Crispr Therapeutics (NASDAQ: CRSP ) stock holds a special place in business history. Source: rafapress / Shutterstock.com Crispr was the first public company to emerge based on the gene editing technology called...
Image source: The Motley Fool. Allogene Therapeutics Inc (NASDAQ: ALLO) Q3 2021 Earnings Call Nov 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Allogene Therapeutics Inc (ALLO) Q3 2021 Earnings Call Transcript ...
Allogene Therapeutics, Inc. (ALLO) Q3 2021 Earnings Conference Call November 04, 2021 5:00 PM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President of Research ...
Allogene Therapeutics (NASDAQ:ALLO): Q3 GAAP EPS of -$0.57 misses by $0.01. The Company had $861.7 million in cash, cash equivalents, and investments as of September 30, 2021. Press Release Allogene continues to expect full year GAAP Operating Expenses to be between $300 and $330 million incl...
New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patie...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...